



Public Pharmacy Benefit Manager (PBM) Transparency Report

12/01/2020

Table of Contents for Public PBM Transparency Report

Cover Letter.....	3
Definitions of Terms Used in This Report.....	4
Transparency Reports, As Submitted by PBMs.....	5

Pharmacy Benefit Manager Transparency Report

In 2019, Minnesota enacted Minn. Stat. Chapter 62W to increase visibility into pharmacy benefit management (PBM) practices and pricing as well as to provide important consumer protections. In order to create greater transparency, the Legislature required PBMs to make two transparency reports: one to plan sponsors and one to the Commerce Department. Commerce is required to publish the public data contained in PBM reporting to the agency on its website.

Reporting process

The Department provided all licensed entities instructions and templates for aggregate and claims level data. The Department then provided a draft public reporting template, requesting feedback from PBMs on whether they believe any of the fields constituted trade secret data. The Department received minimal input on that question.

PBMs were required to submit transparency reporting information to the Department by October 1, 2020¹, including aggregate and claims level data. Due to the varying nature of PBM business models and contracts, a given PBM may be responsible for submitting both types of reports (aggregate and claims level), only one type of report, or neither report. A summary of the types of reports received by the Department are shown in the table at right.

The data published in the attached public reports is drawn from the aggregate report submitted by the each PBM, except data that would be considered trade secret under Minn. Stat. § 13.37. As required by law, the public reports do not contain any information such as claims level data that could lead to identification of a plan sponsor, and to further protect plan sponsor identity, the reports do not include the name of the PBMs submitting them.

Summary of response from PBMs	
Total Licensed PBMs	43
Aggregate Reports Submitted	18
Claims Level Reports Submitted	18
Zero Reports Submitted	5
PBMs not responding to Department	13

Data limitations

- PBMs were given instructions regarding units, rounding, and calculated fields, but the Department cannot guarantee compliance with the reporting instructions at this time.
- The Department has posted data as submitted by the PBMs, except in cases where “total” fields were not provided as instructed, in which case the Department performed the simple calculation to produce the total amount. The report notes instances where the Department performed that calculation and where that calculation created an inconsistency with other data submitted by the PBM.
- The data in this report has not been independently audited.
- While the Department provided a data dictionary to each PBM, some PBMs may have relatively small variations in how they calculated amounts based on their own internal definitions of a given term.

¹ Minn. Stat. § 62W.06 sets the annual deadline for reporting as June 1. This year, however, Commerce extended the deadline to October 1 in Regulatory Guidance 20-28 issued May 18, 2020 utilizing authority granted to the Department by the Legislature under Minnesota Session Laws - 2020, Regular Session, chapter 71, article 2, section 12).

Definitions of Terms Used in PBM Public Transparency Report

WAC

The aggregate wholesale acquisition cost (WAC) of a given drug from the drug's manufacturer (does not include discounts or rebates).

Net WAC

WAC minus any rebates and other fees paid to the PBM with associated claims.

Rebates

Defined in Minn. Stat. § 62W.02 Subd. 17 as all price concessions paid by a drug manufacturer to a pharmacy benefit manager or plan sponsor, including discounts and other price concessions that are based on the actual or estimated utilization of a prescription drug. Rebates also include price concessions based on the effectiveness of a prescription drug as in a value-based or performance-based contract.

Other fees and payments

Any fees and payments, other than those defined as rebates, associated with the pharmaceutical claims in the given category from any source.

Total Rebates and Other Fees and Payments

Calculated as a sum of *total rebates* and *other fees and payments*

Total Rebates and Other Fees and Payments – Non Plan Sponsor

Total amount of rebates and other fees and payments except those that come directly from plan sponsors

Retained Rebates and Other Fees and Payments – Non Plan Sponsor

Total amount of rebates and other fees and payments except those directly from a plan sponsor that are retained by the PBM as revenue for services provided

Retained Rebates and Other Fees and Payments Percentage – Non Plan Sponsor

Calculated as a ratio of *retained rebates and other fees and payments* to *total rebates and other fees and payments*

Therapeutic Category

The grouping of drugs based on similar characteristics such as chemical structure, mechanism of action, or disease treated. PBMs were instructed use the US Pharmacopeia (USP) classification system and report drug groupings at the category level.

Plan Sponsor

A group purchaser as defined under Minn. Stat. § 62J.03; an employer in the case of an employee health benefit plan established or maintained by a single employer; or an employee organization in the case of a health plan established or maintained by an employee organization, an association, joint board trustees, a committee, or other similar group that establishes or maintains the health plan. This term includes a person or entity acting for a pharmacy benefit manager in a contractual or employment relationship in the performance of pharmacy benefit management. Plan sponsor does not include the Minnesota Department of Human Services.

Data for Publication on Commissioner Website - AS REPORTED BY THE PBM

Masked PBM ID 9FXW72IP49
 Data Period Jan 2019-Dec 2019

Notes

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors			
Highest	Lowest	Mean	
0%	0%	0%	0%

Totals During Data Period											
WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor					Net WAC
\$ 73,467	\$ 545	\$ 11,639	\$ 12,184	\$ 0	\$ 0	0%	\$				\$ 61,283

Top 10 Therapeutic Categories by Spend - Descending Order			
Category	WAC	Net WAC	
Anticonvulsants	\$ 20,043	\$	18,309
Analgesics	\$ 11,704	\$	7,444
Antivirals	\$ 9,818	\$	9,589
Skeletal Muscle Relaxants	\$ 8,071	\$	6,493
Antidepressants	\$ 6,861	\$	6,061
Dermatological Agents	\$ 4,231	\$	3,611
Immunological Agents	\$ 3,015	\$	2,955
Blood Products and Modifiers	\$ 2,373	\$	1,807
Respiratory Tract/ Pulmonary Agents	\$ 2,206	\$	1,986
Gastrointestinal Agents	\$ 1,453	\$	993

Data for Publication on Commissioner Website - AS REPORTED BY THE PBM

Masked PBM ID FMF2WEILZX
 Data Period Jan 2019-Dec 2019

Notes
(a) As reported by the PBM but doesn't reconcile to other reported data.
(b) Totals were calculated by the Department based on data reported by the PBM.

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors ^a		
Highest	Lowest	Mean
100%		618

Totals During Data Period ^b										
WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor				Net WAC
\$ 548,299	\$ 75,625	\$ 5,920	\$ 81,544	\$ 0	\$ 0	0%				\$ 466,755

Top 10 Therapeutic Categories by Spend - Descending Order			
Category	WAC	Net WAC	
INSULINS	\$ 71,137	\$	32,318
JANUS KINASE (JAK) INHIBITORS	\$ 64,521	\$	49,181
ARV CMB-NRTI,N(T)RTI, INTEGRASE INHIBITOR	\$ 44,149	\$	41,098
ANTIHYPERGLY,INCRETIN MIMETIC(GLP-1 RECEPTOR AGONIST)	\$ 35,186	\$	24,143
ANTIHYPERLIPIDEMIC - HMG COA REDUCTASE INHIBITORS	\$ 29,833	\$	29,833
ANTIVIRALS, HIV-SPEC, NUCLEOSIDE-NUCLEOTIDE ANALOG	\$ 29,336	\$	28,815
ANTIPSYCHOTICS,ATYPICAL,DOPAMINE,& SEROTONIN ANTAG	\$ 23,583	\$	23,583
Anticonvulsants	\$ 19,874	\$	19,874
Cardiovascular Agents	\$ 14,159	\$	14,159
SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRIS)	\$ 12,432	\$	12,432

Data for Publication on Commissioner Website - AS REPORTED BY THE PBM

Masked PBM ID 160QIKK080
 Data Period Jan 2019-Dec 2019

Notes
(a) As reported by the PBM but doesn't reconcile to other reported data.
(b) Totals were calculated by the Department based on data reported by the PBM.

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors ^a			
Highest	Lowest	Mean	
61%	1%	21%	

Totals During Data Period ^b								
WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC	
\$ 425,994,000	\$ 20,211,000	\$ 402,745,000	\$ 422,975,000	\$ 21,314,000	\$ 2,289,000	11%	\$ 3,013,000	

Top 10 Therapeutic Categories by Spend - Descending Order		
Category	WAC	Net WAC
Blood Glucose Regulators	\$ 52,383,000	\$ (3,351,000)
Immunological Agents	\$ 51,905,000	\$ (1,044,000)
Antivirals	\$ 40,491,000	\$ (904,000)
Unclassified	\$ 39,000,000	\$ (725,000)
Respiratory Tract/ Pulmonary Agents	\$ 31,122,000	\$ 210,000
Central Nervous System Agents	\$ 27,602,000	\$ 771,000
Antineoplastics	\$ 21,957,000	\$ 55,000
Antipsychotics	\$ 20,635,000	\$ 47,000
Dermatological Agents	\$ 19,729,000	\$ 1,081,000
Anticonvulsants	\$ 14,712,000	\$ 536,000

Data for Publication on Commissioner Website - AS REPORTED BY THE PBM

Masked PBM ID OPVQ3A42FU
 Data Period Jan 2019-Dec 2019

Notes

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors			
Highest	Lowest	Mean	
20%	20%	20%	20%

Totals During Data Period								
WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC	
\$ 86,891,806	\$ 16,931,104	\$ 908,635	\$ 17,839,739	\$ 16,931,104	\$ 3,386,074	20%	\$ 69,052,068	

Top 10 Therapeutic Categories by Spend - Descending Order		
Category	WAC	Net WAC
IMMUNOLOGICAL AGENTS > IMMUNE SUPPRESSANTS	\$ 16,529,302	\$ 11,117,514
DERMATOLOGICAL AGENTS > DERMATOLOGICAL AGENTS	\$ 7,172,115	\$ 5,139,044
BLOOD GLUCOSE REGULATORS > INSULINS	\$ 5,901,095	\$ 3,206,608
CENTRAL NERVOUS SYSTEM AGENTS > MULTIPLE SCLEROSIS AGENTS	\$ 4,399,388	\$ 3,781,796
BLOOD GLUCOSE REGULATORS > ANTIDIABETIC AGENTS	\$ 3,976,746	\$ 2,484,947
ANTINEOPLASTICS > MOLECULAR TARGET INHIBITORS	\$ 3,703,101	\$ 3,696,170
RESPIRATORY TRACT/PULMONARY AGENTS > RESPIRATORY TRACT AGENTS, OTHER	\$ 2,596,825	\$ 1,786,029
HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING (SEX HORMONES/MODIFIERS) > ESTROGENS	\$ 2,544,109	\$ 2,433,242
CENTRAL NERVOUS SYSTEM AGENTS > ATTENTION DEFICIT HYPERACTIVITY DISORDER AGENTS, AMPHETAMINES	\$ 2,320,971	\$ 2,086,461
BLOOD PRODUCTS/MODIFIERS/VOLUME EXPANDERS > ANTICOAGULANTS	\$ 1,598,487	\$ 1,133,962

Data for Publication on Commissioner Website - AS REPORTED BY THE PBM

Masked PBM ID M4N0NRS7OR
 Data Period Jan 2019-Dec 2019

Notes

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors			
Highest	Lowest	Mean	
0%	0%	0%	0%

Totals During Data Period									
WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC		
\$ 331,803,000	\$ 50,594,000	\$ 0	\$ 50,594,000	\$ 50,594,000	\$ 0	0%	\$ 281,209,000		

Top 10 Therapeutic Categories by Spend - Descending Order			
Category	WAC	Net WAC	
Immunological Agents	\$ 67,032,000	\$ 56,209,000	
Blood Glucose Regulators	\$ 41,275,000	\$ 24,707,000	
Central Nervous System Agents	\$ 34,424,000	\$ 26,273,000	
Respiratory Tract/Pulmonary Agents	\$ 26,610,000	\$ 19,659,000	
Antineoplastics	\$ 22,765,000	\$ 22,674,000	
Antivirals	\$ 13,935,000	\$ 13,797,000	
Blood Products and Modifiers	\$ 13,141,000	\$ 11,909,000	
Dermatological Agents	\$ 12,767,000	\$ 12,175,000	
Antidepressants	\$ 8,021,000	\$ 8,021,000	
Cardiovascular Agents	\$ 7,994,000	\$ 7,930,000	

Data for Publication on Commissioner Website - AS REPORTED BY THE PBM

Masked PBM ID M8KB9Q6GHZ
 Data Period Jan 2019-Dec 2019

Notes
(a) As reported by the PBM but doesn't reconcile to other reported data.

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors		
Highest	Lowest	Mean

Totals During Data Period								
WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments ^a	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor		Net WAC ^a
\$ 26,330,795	\$ 738,591	\$ 65,809			\$ 65,809	8%		

Top 10 Therapeutic Categories by Spend - Descending Order		
Category	WAC	Net WAC ^a
ANALGESICS - ANTI-INFLAMMATORY	\$ 5,652,852	
DERMATOLOGICALS	\$ 1,989,463	
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	\$ 1,880,323	
ANTIDIABETICS	\$ 1,839,995	
ANTIASTHMATIC AND BRONCHODILATOR AGENTS	\$ 1,218,696	
Psychotherapeutic and Neurological Agents - Misc.	\$ 1,146,917	
ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREXIANTS	\$ 1,013,044	
ANTIDIABETICS	\$ 959,717	
DERMATOLOGICALS	\$ 819,791	
ANTIASTHMATIC AND BRONCHODILATOR AGENTS	\$ 638,774	

Data for Publication on Commissioner Website - AS REPORTED BY THE PBM

Masked PBM ID NZCD989Z1J
 Data Period Jan 2019-Dec 2019

Notes

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors			
Highest	Lowest	Mean	
0%	0%	0%	0%

Totals During Data Period									
WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC		
\$ 1,913,000	\$ 219,000	\$ 8,000	\$ 227,000	\$ 219,000	\$ 0	0%	\$ 1,701,000		

Top 10 Therapeutic Categories by Spend - Descending Order			
Category	WAC	Net WAC	
Immunological Agents	\$ 523,000	\$ 487,000	
Analgesics	\$ 305,000	\$ 268,000	
Sleep Disorder Agents	\$ 300,000	\$ 280,000	
Antivirals	\$ 231,000	\$ 220,000	
Anticonvulsants	\$ 177,000	\$ 151,000	
Blood Glucose Regulators	\$ 105,000	\$ 86,000	
Antidepressants	\$ 65,000	\$ 58,000	
Blood Products/Modifiers/Volume Expanders	\$ 53,000	\$ 43,000	
Respiratory Tract/Pulmonary Agents	\$ 49,000	\$ 33,000	
Skeletal Muscle Relaxants	\$ 47,000	\$ 42,000	

Data for Publication on Commissioner Website - AS REPORTED BY THE PBM

Masked PBM ID GB94XMQ219
 Data Period Jan 2019-Dec 2019

Notes
(a) Totals were calculated by the Department based on data reported by the PBM.

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors			
Highest	Lowest	Mean	
0%	0%	0%	0%

Totals During Data Period ^a									
WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC		
\$ 509,638	\$ 49,925	\$ 18,416	\$ 68,342	\$ 50,353	\$ 0	0%	\$	\$	441,296

Top 10 Therapeutic Categories by Spend - Descending Order			
Category	WAC	Net WAC	
Products Without a USP Category	\$ 260,659	\$	258,283
Blood Glucose Regulators	\$ 59,984	\$	40,658
Dermatological Agents	\$ 47,518	\$	34,138
Immunological Agents	\$ 26,386	\$	24,620
Cardiovascular Agents	\$ 24,241	\$	16,064
Respiratory Tract/Pulmonary Agents	\$ 17,870	\$	8,845
Central Nervous System Agents	\$ 13,589	\$	12,995
Gastrointestinal Agents	\$ 10,174	\$	7,764
Antidepressants	\$ 8,872	\$	6,419
Blood Products and Modifiers	\$ 5,534	\$	4,075

Data for Publication on Commissioner Website - AS REPORTED BY THE PBM

Masked PBM ID KABDFCFWND
 Data Period Jan 2019-Dec 2019

Notes
(a) As reported by the PBM but doesn't reconcile to other reported data.

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors ^a			
Highest	Lowest	Mean	
100%	0%	50%	

Totals During Data Period									
WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC		
\$ 363,911,000	\$ 10,000	\$ 222,000	\$ 232,000	\$ 232,000	\$ 222,000	96%	\$ 363,679,000		

Top 10 Therapeutic Categories by Spend - Descending Order			
Category	WAC	Net WAC	
Immunological Agents	\$ 80,223,000	\$ 80,217,000	
Blood Glucose Regulators	\$ 49,641,000	\$ 49,624,000	
Central Nervous System Agents	\$ 36,694,000	\$ 36,686,000	
Respiratory Tract/Pulmonary Agents	\$ 28,237,000	\$ 28,219,000	
Antineoplastics	\$ 27,433,000	\$ 27,431,000	
Antivirals	\$ 19,560,000	\$ 19,557,000	
Blood Products and Modifiers	\$ 13,546,000	\$ 13,543,000	
Dermatological Agents	\$ 11,861,000	\$ 11,854,000	
Cardiovascular Agents	\$ 10,746,000	\$ 10,700,000	
Antidepressants	\$ 10,025,000	\$ 9,999,000	

Data for Publication on Commissioner Website - AS REPORTED BY THE PBM

Masked PBM ID CF4194CK8X
 Data Period Jan 2019-Dec 2019

Notes
(a) As reported by the PBM but doesn't reconcile to other reported data.

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors			
Highest	Lowest	Mean	
0%	0%	0%	0%

Totals During Data Period										
WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments ^a	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor				Net WAC
\$ 27,308,406	\$ 5,482,802	\$ 0	\$ 0	\$ 0	\$ 0	0%	\$	21,825,604		

Top 10 Therapeutic Categories by Spend - Descending Order			
Category	WAC	Net WAC	
Immunological Agents	\$ 7,625,842	\$	6,228,653
Blood Glucose Regulators	\$ 7,285,234	\$	5,508,189
Respiratory Tract/ Pulmonary Agents	\$ 2,811,630	\$	2,059,420
Cardiovascular Agents	\$ 2,115,267	\$	1,964,480
Antivirals	\$ 1,636,800	\$	1,607,760
Central Nervous System Agents	\$ 1,375,605	\$	791,751
Blood Products and Modifiers	\$ 809,472	\$	703,456
Antimycobacterials	\$ 622,100	\$	616,213
Hormonal Agents, Suppressant (Pituitary)	\$ 577,099	\$	222,377
Anticonvulsants	\$ 413,518	\$	395,335

Data for Publication on Commissioner Website - AS REPORTED BY THE PBM

Masked PBM ID 1HQMMW5N

Data Period CY2019

Notes
(a) Totals were calculated by the Department based on data reported by the PBM.

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors		
Highest	Lowest	Mean
90%	0%	39%

Totals During Data Period ^a								
WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC	
\$ 688,812,134	\$ 96,336,197	\$ 15,651,526	\$ 111,987,723	\$ 107,717,364	\$ 41,796,331	39%	\$ 576,824,411	

Top 10 Therapeutic Categories by Spend - Descending Order			
Category	WAC	Net WAC	
BLOOD GLUCOSE REGULATORS	\$ 90,744,720	\$	49,863,299
ANTINEOPLASTICS	\$ 68,564,933	\$	67,855,149
RESPIRATORY TRACT/ PULMONARY AGENTS	\$ 67,354,426	\$	52,958,692
ANTIVIRALS	\$ 44,585,838	\$	41,238,470
IMMUNOLOGICAL AGENTS	\$ 43,054,989	\$	32,365,878
CENTRAL NERVOUS SYSTEM AGENTS	\$ 39,650,813	\$	35,305,020
CARDIOVASCULAR AGENTS	\$ 39,014,410	\$	35,216,593
ANALGESICS	\$ 31,400,574	\$	29,206,601
BLOOD PRODUCTS/ MODIFIERS/ VOLUME EXPANDERS	\$ 27,107,338	\$	21,084,291
HORMONAL AGENTS, STIMULANT/ REPLACEMENT/ MODIFYING (SEX HORMONES/ MODIFIERS)	\$ 24,325,514	\$	22,419,752

Data for Publication on Commissioner Website - AS REPORTED BY THE PBM

Masked PBM ID SXXXBYBREM

Data Period CY2019

Notes
(a) As reported by the PBM but doesn't reconcile to other reported data.

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors ^a			
Highest	Lowest	Mean	
100%	0%	76%	

Totals During Data Period										
WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor				Net WAC
\$ 55,383,050	\$ 1,938,087	\$ 1,456,779	\$ 3,394,866	\$ 2,036,112	\$ 98,025	5%				\$ 51,988,184

Top 10 Therapeutic Categories by Spend - Descending Order			
Category	WAC	Net WAC	
DIABETIC THERAPY	\$ 7,856,680	\$ 7,011,045	
MISCELLANEOUS	\$ 7,783,039	\$ 7,721,679	
ANTIARTHRITICS	\$ 4,693,509	\$ 4,551,913	
ATARACTICS-TRANQUILIZERS	\$ 4,184,464	\$ 4,038,675	
BRONCHIAL DILATORS	\$ 3,780,822	\$ 3,612,771	
ANTICONVULSANTS	\$ 2,306,177	\$ 2,193,056	
ANTIVIRALS	\$ 2,039,775	\$ 1,977,586	
PSYCHOSTIMULANTS-ANTIDEPRESSANTS	\$ 2,019,629	\$ 1,843,615	
AMPHETAMINE PREPARATIONS	\$ 1,971,069	\$ 1,897,044	
ANTINEOPLASTICS	\$ 1,850,928	\$ 1,844,997	

Data for Publication on Commissioner Website - AS REPORTED BY THE PBM

Masked PBM ID Y8LWDBOA1

Data Period CY2019

Notes

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors			
Highest	Lowest	Mean	
0%	0%	0%	0%

Totals During Data Period									
WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC		
\$ 781,634	\$ 379,071	\$ 0	\$ 379,071	\$ 0	\$ 0	0%	\$ 402,564		

Top 10 Therapeutic Categories by Spend - Descending Order			
Category	WAC	Net WAC	
Immunological Agents	\$ 271,133	\$ 120,914	
Sleep Disorder Agents	\$ 184,283	\$ 184,283	
Bulk Chemicals	\$ 99,995	\$ 99,995	
Blood Glucose Regulators	\$ 59,759	\$ (23,454)	
Antineoplastics	\$ 40,213	\$ 40,213	
Hormonal Agents	\$ 21,960	\$ 15,384	
Agents to Treat Blood Disorders	\$ 20,771	\$ 11,363	
Cardiovascular Agents	\$ 12,780	\$ 12,682	
Ophthalmic Agents	\$ 7,602	\$ 3,531	
Respiratory Tract Agents	\$ 7,560	\$ (29,467)	

Data for Publication on Commissioner Website - AS REPORTED BY THE PBM

Masked PBM ID YFEPHOHWEF

Data Period CY2019

Notes
(a) As reported by the PBM but doesn't reconcile to other reported data.
(b) Totals were calculated by the Department based on data reported by the PBM.

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors ^a			
Highest	Lowest	Mean	
25%	0%	20%	20%

Totals During Data Period ^b									
WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC		
\$ 124,969	\$ 23,331	\$ 0	\$ 23,331	\$ 23,331	\$ 9,000	39%	\$	\$	101,638

Top 10 Therapeutic Categories by Spend - Descending Order			
Category	WAC	Net WAC	
Immune Suppressants	\$ 72,437	\$	67,739
Antidiabetic Agents	\$ 14,320	\$	12,235
Insulins	\$ 10,535	\$	4,955
Dyslipidemics, Other	\$ 7,845	\$	7,603
Miscellaneous Therapeutic Agents	\$ 3,659	\$	3,621
Respiratory Tract/ Pulmonary Agents	\$ 3,145	\$	2,576
Anti-inflammatories, Inhaled Corticosteroids	\$ 2,746	\$	2,150
Bronchodilators, Sympathomimetic	\$ 2,100	\$	1,667
Ophthalmic Anti-allergy Agents	\$ 1,246	\$	1,168
Attention Deficit Hyperactivity Disorder Agents, Amphetamines	\$ 931	\$	(115)

Data for Publication on Commissioner Website - AS REPORTED BY THE PBM

Masked PBM ID MIFQW92IP

Data Period CY2019

Notes
(a) Totals were calculated by the Department based on data reported by the PBM.

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors		
Highest	Lowest	Mean
75%	0%	5%

Totals During Data Period ^a									
WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor			Net WAC
\$ 72,793,475	\$ 17,097,438	\$ 1,879,099	\$ 18,976,537	\$ 18,976,537	\$ 1,017,621	5%	\$		\$ 53,816,938

Top 10 Therapeutic Categories by Spend - Descending Order		
Category	WAC	Net WAC
IMMUNOLOGICAL AGENTS	\$ 13,339,010	\$ 8,134,609
BLOOD GLUCOSE REGULATORS	\$ 11,566,295	\$ 4,623,735
CENTRAL NERVOUS SYSTEM AGENTS	\$ 7,115,713	\$ 5,871,952
RESPIRATORY TRACT/ PULMONARY AGENTS	\$ 5,731,445	\$ 4,527,036
ANTIVIRALS	\$ 5,661,592	\$ 5,176,501
ANTINEOPLASTICS	\$ 5,099,381	\$ 5,078,677
DERMATOLOGICAL AGENTS	\$ 4,267,591	\$ 2,691,673
CARDIOVASCULAR AGENTS	\$ 2,515,817	\$ 2,398,292
BLOOD PRODUCTS/ MODIFIERS/ VOLUME EXPANDERS	\$ 2,466,801	\$ 1,835,774
GENETIC OR ENZYME DISORDER: REPLACEMENT, MODIFIERS, TREATMENT	\$ 2,383,131	\$ 1,997,689

Data for Publication on Commissioner Website - AS REPORTED BY THE PBM

Masked PBM ID 8ANP263BS

Data Period CY2019

Notes

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors		
Highest	Lowest	Mean
100%	100%	100%

Totals During Data Period									
WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC		
\$ 5,335,368	\$ 649,582	\$ 0	\$ 649,582	\$ 649,582	\$ 649,582	100%	\$ 4,685,786		

Top 10 Therapeutic Categories by Spend - Descending Order		
Category	WAC	Net WAC
ANALGESICS - OPIOID	\$ 1,564,463	\$ 1,320,554
ANTICONVULSANTS	\$ 1,335,388	\$ 1,160,998
DERMATOLOGICALS	\$ 503,200	\$ 495,716
ANTIASTHMATIC AND BRONCHODILATOR AGENTS	\$ 277,427	\$ 212,144
ANTIDEPRESSANTS	\$ 200,753	\$ 193,637
ANALGESICS - ANTI-INFLAMMATORY	\$ 189,246	\$ 189,246
ANTICOAGULANTS	\$ 127,649	\$ 97,865
MUSCULOSKELETAL THERAPY AGENTS	\$ 113,709	\$ 113,566
ENDOCRINE AND METABOLIC AGENTS - MISC.	\$ 95,258	\$ 48,399
ANTIVIRALS	\$ 85,939	\$ 85,590